A research report on Japan's stool antigen testing market has been released, forecasting a market size of approximately $215.81 million as of 2025 and approximately $448.95 million by 2035.
Japan's stool antigen testing market is estimated at approximately $215.81 million as of 2025 and is expected to expand at a CAGR of 7.6% from 2026 to 2035, reaching approximately $448.95 million by 2035. Factors supporting growth include efforts to address Helicobacter pylori infection, gastric cancer prevention, rising demand for non-invasive testing, and the expansion of laboratory automation and preventive healthcare. By segment, Bacterial Antigen Test is the largest testing type, accounting for 50.3%, while ELISA accounts for 48.2% of the technology segment and H. pylori Detection accounts for 41.6% of applications.
The testing method is non-invasive and detects pathogen antigens in stool samples. The market includes antigen detection kits, automated analysis platforms, and point-of-care testing (POCT) equipment. H. pylori is described as the most important source of demand, with testing used to confirm the presence or absence of infection after eradication treatment and as part of gastric cancer prevention strategies. At the same time, factors weighing on the market include a decline in the population undergoing initial diagnosis as prevalence falls among younger people.
ELISA is the leading technology, while Lateral Flow Immunoassays are also positioned for outpatient testing where rapid results are required. Going forward, high-sensitivity testing using monoclonal antibodies and the introduction of automated workflows are expected to become increasingly important. The view presented is that improving processing capacity at hospitals and testing centers and promoting the shift toward outpatient care will be key to market expansion.
The competitive landscape includes major IVD companies such as Abbott Laboratories, bioMérieux, Thermo Fisher Scientific, and Roche. Competition will center not only on testing kits but also on automated immunoassay analyzers, reagents, and the integration of hospital laboratories. However, the materials do not identify the products offered by each company in Japan or their market shares.